The role of tryptophan-AhR signaling in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD): implications for therapeutic strategies.

Authors

Yinan Zhao, Shuhao Cheng, Jiu Liang, Guoying Yu

Published in

Frontiers in immunology. Volume 17. Pages 1806118. Epub Mar 18, 2026.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a significant global health concern, closely associated with metabolic syndrome and characterized by hepatic fat accumulation, inflammation, and fibrosis. While the pathogenesis of MASLD is multifactorial, recent research has highlighted the role of the tryptophan-aryl hydrocarbon receptor (AhR) signaling pathway in influencing both immune and metabolic functions in the liver. Tryptophan, an essential amino acid, is metabolized into various bioactive metabolites, such as kynurenine, that activate AhR. This activation modulates cellular processes including inflammation, oxidative stress, and lipid metabolism. Emerging evidence suggests that dysregulated tryptophan metabolism and AhR signaling contribute to the progression of MASLD, particularly through immune modulation and alterations in metabolic pathways. This perspective aims to provide an overview of the current understanding of tryptophan-AhR signaling in MASLD, discussing its potential as a therapeutic target and the challenges associated with targeting this pathway. Future research directions are proposed to explore how modulation of the tryptophan-AhR axis could offer novel therapeutic strategies for MASLD, providing new insights into its treatment and management.

PMID:
41929520
Bibliographic data and abstract were imported from PubMed on 11 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.